AUPH
Price
$12.08
Change
-$0.03 (-0.25%)
Updated
Aug 28 closing price
Capitalization
1.59B
62 days until earnings call
GOSS
Price
$2.40
Change
-$0.07 (-2.85%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
545.71M
69 days until earnings call
Interact to see
Advertisement

AUPH vs GOSS

Header iconAUPH vs GOSS Comparison
Open Charts AUPH vs GOSSBanner chart's image
Aurinia Pharmaceuticals
Price$12.08
Change-$0.03 (-0.25%)
Volume$1.08M
Capitalization1.59B
Gossamer Bio
Price$2.40
Change-$0.07 (-2.85%)
Volume$106.51K
Capitalization545.71M
AUPH vs GOSS Comparison Chart in %
Loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. GOSS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a StrongBuy and GOSS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (AUPH: $12.08 vs. GOSS: $2.40)
Brand notoriety: AUPH and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 46% vs. GOSS: 118%
Market capitalization -- AUPH: $1.59B vs. GOSS: $545.71M
AUPH [@Biotechnology] is valued at $1.59B. GOSS’s [@Biotechnology] market capitalization is $545.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, both AUPH and GOSS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 2 TA indicator(s) are bullish while GOSS’s TA Score has 4 bullish TA indicator(s).

  • AUPH’s TA Score: 2 bullish, 6 bearish.
  • GOSS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than AUPH.

Price Growth

AUPH (@Biotechnology) experienced а 0.00% price change this week, while GOSS (@Biotechnology) price change was +10.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

AUPH is expected to report earnings on Oct 30, 2025.

GOSS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($1.59B) has a higher market cap than GOSS($546M). GOSS YTD gains are higher at: 165.311 vs. AUPH (34.521). AUPH has higher annual earnings (EBITDA): 86.5M vs. GOSS (-128.6M). AUPH has more cash in the bank: 315M vs. GOSS (213M). AUPH has less debt than GOSS: AUPH (81.8M) vs GOSS (203M). AUPH has higher revenues than GOSS: AUPH (260M) vs GOSS (40.2M).
AUPHGOSSAUPH / GOSS
Capitalization1.59B546M291%
EBITDA86.5M-128.6M-67%
Gain YTD34.521165.31121%
P/E Ratio28.09N/A-
Revenue260M40.2M647%
Total Cash315M213M148%
Total Debt81.8M203M40%
FUNDAMENTALS RATINGS
AUPH vs GOSS: Fundamental Ratings
AUPH
GOSS
OUTLOOK RATING
1..100
7719
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (55) in the Pharmaceuticals Major industry is in the same range as AUPH (65) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as AUPH (37) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHGOSS
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 22 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVVYX24.74N/A
N/A
Macquarie International Core Eq Y
RCOCX46.05N/A
N/A
Victory RS Large Cap Alpha C
MGFYX10.28N/A
N/A
MassMutual Global Svc
JDISX16.57N/A
N/A
JHancock Disciplined Value Intl R2
TISDX11.95N/A
N/A
Transamerica Intl Sust Eq A

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-0.25%
JSPR - AUPH
44%
Loosely correlated
-2.07%
VCYT - AUPH
39%
Loosely correlated
+4.68%
ROIV - AUPH
38%
Loosely correlated
-0.42%
GOSS - AUPH
37%
Loosely correlated
-2.44%
CRNX - AUPH
35%
Loosely correlated
+0.82%
More